After adjusting for HbA1c, BMI, and diabetes duration through ANCOVA, patients on insulin therapy presented significantly higher NOX2 levels (22.8 ± 1.5 ng/mL) compared to those on metformin or DPP-4 inhibitors alone (p = 0.041 and p = 0.028, respectively). Here, CYBB is linked to diabetes mellitus.